↓ Skip to main content

Endocannabinoids

Overview of attention for book
Attention for Chapter 7: Endocannabinoids
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#19 of 498)
  • High Attention Score compared to outputs of the same age (93rd percentile)

Mentioned by

blogs
1 blog
twitter
22 tweeters
facebook
12 Facebook pages
wikipedia
1 Wikipedia page
googleplus
4 Google+ users

Citations

dimensions_citation
14 Dimensions

Readers on

mendeley
80 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Chapter title
Endocannabinoids
Chapter number 7
Book title
Endocannabinoids
Published in
Handbook of experimental pharmacology, January 2015
DOI 10.1007/978-3-319-20825-1_7
Pubmed ID
Book ISBNs
978-3-31-920824-4, 978-3-31-920825-1
Authors

Pryce, Gareth, Baker, David, Gareth Pryce, David Baker

Editors

Roger G. Pertwee

Abstract

There are numerous reports that people with multiple sclerosis (MS) have for many years been self-medicating with illegal street cannabis or more recently medicinal cannabis to alleviate the symptoms associated with MS and also amyotrophic lateral sclerosis (ALS). These anecdotal reports have been confirmed by data from animal models and more recently clinical trials on the ability of cannabinoids to alleviate limb spasticity, a common feature of progressive MS (and also ALS) and neurodegeneration. Experimental studies into the biology of the endocannabinoid system have revealed that cannabinoids have efficacy, not only in symptom relief but also as neuroprotective agents which may slow disease progression and thus delay the onset of symptoms. This review discusses what we now know about the endocannabinoid system as it relates to MS and ALS and also the therapeutic potential of cannabinoid therapeutics as disease-modifying or symptom control agents, as well as future therapeutic strategies including the potential for slowing disease progression in MS and ALS.

Twitter Demographics

The data shown below were collected from the profiles of 22 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 80 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Mexico 1 1%
Hungary 1 1%
Austria 1 1%
Unknown 77 96%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 16 20%
Researcher 12 15%
Student > Postgraduate 8 10%
Student > Master 8 10%
Student > Ph. D. Student 8 10%
Other 15 19%
Unknown 13 16%
Readers by discipline Count As %
Neuroscience 15 19%
Medicine and Dentistry 14 18%
Biochemistry, Genetics and Molecular Biology 9 11%
Psychology 7 9%
Agricultural and Biological Sciences 7 9%
Other 12 15%
Unknown 16 20%

Attention Score in Context

This research output has an Altmetric Attention Score of 35. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 October 2016.
All research outputs
#664,065
of 16,287,282 outputs
Outputs from Handbook of experimental pharmacology
#19
of 498 outputs
Outputs of similar age
#16,535
of 266,745 outputs
Outputs of similar age from Handbook of experimental pharmacology
#1
of 3 outputs
Altmetric has tracked 16,287,282 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 498 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.9. This one has done particularly well, scoring higher than 96% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 266,745 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 3 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them